Analysts Set uniQure (NASDAQ:QURE) Target Price at $38.89

Shares of uniQure (NASDAQ:QURE) have earned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $38.89.

Several equities research analysts have weighed in on QURE shares. Wells Fargo & Company reduced their price objective on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of uniQure in a research report on Tuesday, March 4th. The Goldman Sachs Group boosted their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald raised their target price on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th.

uniQure Stock Performance

uniQure stock opened at $13.13 on Tuesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company’s 50-day moving average price is $13.80 and its 200-day moving average price is $10.70. The company has a market cap of $710.03 million, a PE ratio of -2.65 and a beta of 0.36.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at $6,703,461.66. The trade was a 4.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 10,438 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $107,407.02. Following the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at $2,240,441.70. The trade was a 4.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,830 shares of company stock worth $961,401. Insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Voloridge Investment Management LLC purchased a new stake in uniQure during the fourth quarter worth $3,129,000. Woodline Partners LP bought a new position in shares of uniQure in the 4th quarter worth $2,484,000. Two Sigma Advisers LP lifted its stake in shares of uniQure by 1.4% during the 4th quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock worth $13,367,000 after purchasing an additional 10,400 shares during the last quarter. Two Sigma Investments LP boosted its position in uniQure by 9.2% during the fourth quarter. Two Sigma Investments LP now owns 878,884 shares of the biotechnology company’s stock valued at $15,521,000 after purchasing an additional 73,988 shares in the last quarter. Finally, Stempoint Capital LP purchased a new position in uniQure in the fourth quarter valued at about $1,589,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.